跳到主要导航 跳到搜索 跳到主要内容

Drug prevention and control of ventilator-associated pneumonia

  • Xi'an Jiaotong University

科研成果: 期刊稿件 › 文章 › 同行评审

15 引用 (Scopus)

摘要

Ventilator-associated pneumonia (VAP) is one of the most prevalent and serious complications of mechanical ventilation, which is considered a common nosocomial infection in critically ill patients. There are some great options for the prevention of VAP: (i) minimize ventilator exposure; (ii) intensive oral care; (iii) aspiration of subglottic secretions; (iv) maintain optimal positioning and encourage mobility; and (v) prophylactic probiotics. Furthermore, clinical management of VAP depends on appropriate antimicrobial therapy, which needs to be selected based on individual patient factors, such as previous antibacterial therapy, history of hospitalization or mechanical ventilation, and bacterial pathogens and antibiotic resistance patterns. In fact, antibiotic resistance has exponentially increased over the last decade, and the isolation of a multidrug-resistant (MDR) pathogen has been identified as an independent predictor of inadequate initial antibiotic therapy and which is significantly associated with increased mortality. Multiple attempts were used in the treatment of VAP, such as novel antibacterial agents, inhaled antibiotics and monoclonal antibodies. In this review, we summarize the current therapeutic options for the prevention and treatment of VAP, aiming to better management of VAP in clinical practice.

源语言英语
期刊论文编号298
期刊Frontiers in Pharmacology
卷10
期MAR
DOI
出版状态已出版 - 2019

学术指纹

探究 'Drug prevention and control of ventilator-associated pneumonia' 的科研主题。它们共同构成独一无二的学术指纹。

引用此